Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
Luis Paz‐Ares(Hospital Universitario 12 De Octubre), Dariusz M. Kowalski(The Maria Sklodowska-Curie National Research Institute of Oncology), Filiz Çay Şenler, Mahmut Gümüş(Istanbul Medeniyet University), Gregory M. Lubiniecki(Merck & Co., Inc., Rahway, NJ, USA (United States)), Alexander Luft, Bárbara Hermes(Klinikum im Friedrichshain), Bilal Piperdi(Université Toulouse III - Paul Sabatier), Julien Mazières(Université Toulouse III - Paul Sabatier), Ying Cheng(Jilin Province Tumor Hospital), Tibor Csőszi, Jerónimo Rafael Rodríguez‐Cid(Hospital Médica Sur), Ali Tafreshi, Shunichi Sugawara(Sendai Kousei Hospital), Balázs Halmos(Montefiore Medical Center), Terufumi Kato(Taipei Veterans General Hospital), Andrea Fülöp(Országos Korányi Tbc és Pulmonológiai Intézet), Xiaodong Li(Université Toulouse III - Paul Sabatier), David Vicente(Université Toulouse III - Paul Sabatier), Silvia Novello(University of Turin), Jonathan Wilson(Université Toulouse III - Paul Sabatier), Ki Hyeong Lee(Chungbuk National University Hospital)
Cited by 3,681
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k